The purpose of this observational study was to evaluate the long-term efficacy and safety of a paclitaxel-coated balloon catheter in coronary in-stent restenosis (ISR) patients. The primary endpoint was target lesion failure (TLF, a composite of cardiac death, target-vessel MI, or target lesion revascularization) at 12 months.
260 subjects treated with a paclitaxel-coated balloon (Genoss® DCB) in patients with coronary in-stent restenosis (ISR) will be recruited and followed up to 12 months. All enrolled patients treated with Genoss DCB in patients with coronary in-stent restenosis (ISR) will be included in the analysis unless there is a valid reason or rationale for it, and the final statistical analysis will follow the intention-to-treat (ITT) principle as assigned. Standard descriptive statistics will be used for patient baseline characteristics, lesions, procedures, and clinical event outcomes. Categorical variables will be presented as percentages and numbers and compared using chi-square or Fisher's exact test. Continuous variables will appear as mean, standard deviation or median, and interquartile range, and will be compared with Student's T-test or Wilcoxon rank sum test, and the normal value of the standard variable distribution will be predicted through histogram, skewness, kurtosis, and Kolmogorov Smirnov one sample test.
Study Type
OBSERVATIONAL
Enrollment
260
Paclitaxel coated balloon with a shellac plus vitamin E excipient
Kosin University Gospel Hospital
Busan, Busan, South Korea
Kangwon National University Hospital
Chuncheon, Gangwon-do, South Korea
Korea University Ansan Hospital
Ansan-si, Gyeonggi-do, South Korea
Targeted lesion failure
A composite of cardiac death, target-vessel MI, or target lesion revascularization
Time frame: 12 months
Major adverse cardiovascular events
A composite of all-cause death, MI, or revascularization
Time frame: 12 months
All-cause death
All-cause death and cardiac death
Time frame: 12 months
Any MI
Any MI and target vessel MI
Time frame: 12 months
Any revascularization
Any revascularization and ischemic driven target lesion revascularization
Time frame: 12 months
Major bleeding events, BARC 3, 5
A composite rate of major bleeding events, BARC 3, 5
Time frame: 12 months
Any Stroke
Ischemic or hemorrhagic stroke
Time frame: 12 months
Any stent thrombosis
Definite or probable stent thrombosis (acute, subacute, late)
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Inje University Ilsan Paik Hospital
Goyang-si, Gyeonggi-do, South Korea
National Health Insurance Service Ilsan Hospital
Goyang-si, Gyeonggi-do, South Korea
Yongin Severance Hospital, Yonsei University
Yongin-si, Gyeonggi-do, South Korea
Kyungpook National University College Hospital
Daegu, Gyeongsangnam-do, South Korea
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, South Korea
Jeonbuk National University Hospital
Jeonju, Jeollabuk-do, South Korea
Korea University ANAM Hospital
Seoul, Seoul, South Korea